atomoxetine
Phase 3Completed 0 watching 0 views this week📈 Rising
77
Development Stage
✓
Pre-clinical✓
Phase 1✓
Phase 24
Phase 35
ApprovedIndication / Disease
Attention Deficit Hyperactivity Disorder
Conditions
Attention Deficit Hyperactivity Disorder
Trial Timeline
May 1, 2004 → Jun 1, 2006
NCT ID
NCT00191880About atomoxetine
atomoxetine is a phase 3 stage product being developed by Eli Lilly for Attention Deficit Hyperactivity Disorder. The current trial status is completed. This product is registered under clinical trial identifier NCT00191880. Target conditions include Attention Deficit Hyperactivity Disorder.
Hype Score Breakdown
Clinical
27
Activity
18
Company
10
Novelty
9
Community
10
Clinical Trials (20)
| NCT ID | Phase | Status |
|---|---|---|
| NCT01177943 | Phase 1 | Completed |
| NCT00969618 | Phase 3 | Completed |
| NCT00760747 | Approved | Completed |
| NCT00687609 | Approved | Terminated |
| NCT00636818 | Phase 2 | Completed |
| NCT00530335 | Phase 2 | Completed |
| NCT00471354 | Approved | Completed |
| NCT00918567 | Approved | Completed |
| NCT00299234 | Approved | Terminated |
| NCT00320528 | Phase 3 | Completed |
| NCT00252278 | Approved | UNKNOWN |
| NCT00255138 | Phase 3 | Withdrawn |
| NCT00953862 | Pre-clinical | Completed |
| NCT00191633 | Approved | Completed |
| NCT00286949 | Pre-clinical | Completed |
| NCT00488163 | Approved | Completed |
| NCT00191737 | Phase 3 | Completed |
| NCT00191516 | Phase 3 | Completed |
| NCT00191880 | Phase 3 | Completed |
| NCT00191035 | Approved | Completed |
Competing Products
20 competing products in Attention Deficit Hyperactivity Disorder